Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.

@article{Kiser2005VasopressinNO,
  title={Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.},
  author={Tyree H Kiser and Douglas N. Fish and Marilee D. Obritsch and Rose Jung and Robert E Maclaren and Chirag R Parikh},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2005},
  volume={20 9},
  pages={1813-20}
}
BACKGROUND Hepatorenal syndrome (HRS) is a severe complication of cirrhosis and is associated with high mortality. Ornipressin and terlipressin are effective in treatment of HRS, but are not available in the USA. The efficacy of vasopressin (AVP) and octreotide (OCT) infusions, commonly utilized in the USA, in the treatment of HRS is unknown. This study aims to evaluate the effects of AVP and OCT on renal function, systemic haemodynamics and clinical outcomes in HRS. METHODS This… CONTINUE READING
29 Citations
20 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Similar Papers

Loading similar papers…